RELAPSED PERIPHERAL T-CELL LYMPHOMA
Clinical trials for RELAPSED PERIPHERAL T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED PERIPHERAL T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED PERIPHERAL T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Virus-Immunotherapy combo targets Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-phase trial tests a specially modified virus (VSV-hIFNβ-NIS) combined with two immunotherapy drugs (ipilimumab and cemiplimab) in adults with relapsed or refractory T-cell lymphoma. The virus is designed to kill cancer cells without harming healthy ones, while the immu…
Matched conditions: RELAPSED PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 03:37 UTC
-
New combo attack on hard-to-treat lymphoma shows promise in early trial
Disease control Recruiting nowThis study tests two drugs, pembrolizumab and olaparib, together in people with a rare type of blood cancer called peripheral T-cell lymphoma that has returned or not improved with prior therapy. The goal is to see if the combination can shrink or control the cancer. About 24 adu…
Matched conditions: RELAPSED PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated May 26, 2026 03:34 UTC